About OnCusp

OnCusp Therapeutics, Inc. is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building biotech startups, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.

We deliver

hope to cancer

patients worldwide.

Culture and Values

At OnCusp Therapeutics, we cultivate a culture rooted in medical innovation and a steadfast commitment to societal betterment. Our ethos revolves around a blend of precise, goal-oriented strategies and a deep-seated belief in forging win-win partnerships. Our team’s agility is balanced by accountability, ensuring that quality remains uncompromised. We embrace calculated risks, leveraging our collective experience to seize transformative opportunities. Honesty serves as the bedrock of our interactions, shaping partnerships that prioritize fairness and transparency in equitable risk-sharing and reward distribution. Through our extensive network and deep-rooted knowledge, we relentlessly pursue value creation while remaining steadfastly focused on our ultimate goal of improving patient outcomes.

Company Milestones

  • Mar 2024

    Became a clinical stage company with first patient dosed in Phase 1 clinical trial of CUSP06

  • Dec 2023

    Completed an oversubscribed Series A financing for $100 million

  • Aug 2023

    Received FDA clearance for the Phase I clinical trial of CUSP06

  • Apr 2023

    Showcased potent Anti-Tumor activity of its CDH6 ADC at AACR Annual Meeting 2023

  • Aug 2022

    Raised $14M in Series Seed Plus financing

  • Apr 2022

    Established global partnership (excluding China) with a Chinese biotech, to develop CUSP06

  • Oct 2021

    Established global partnership (excluding China) with a Chinese biotech to discover and develop CUSP03

  • Sept 2021

    Initiation of first In-House Program CUSP02

  • Jun 2021

    Opened New York office

  • Apr 2021

    Opened Shanghai office

  • Apr 2021

    - Company Founded
    - Completed $25 million seed round financing and started operations

Management Team

Scientific Advisory Board